EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, BBIO: Bridgebio Pharma Inc

23 Jul 26 15:59
LAST:

82.93

CHANGE:
 0.27		OPEN:
82.30		HIGH:
83.53		ASK:
0.00		VOLUME:
893.4K
CHG(%):
0.33		PREV:
82.66		LOW:
81.77		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
23 Jul 2682.4083.5381.7782.931.53M
22 Jul 2682.4782.8881.0282.661.57M
21 Jul 2680.8082.6180.7682.451.39M
20 Jul 2681.9383.1680.7080.761.75M
17 Jul 2679.1082.5678.9881.381.44M
16 Jul 2683.0683.0680.1780.303.53M
15 Jul 2683.4883.5882.0982.661.96M
14 Jul 2682.3084.5981.5084.092.74M
13 Jul 2684.8485.3881.3783.083.38M
10 Jul 2690.8191.0084.8685.896.38M

PROFILE

Name:Bridgebio Pharma Inc
About:BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Sector:Healthcare
Industry:Biotechnology
Address:3160 Porter Drive, Palo Alto, CA, United States, 94304
Website:https://bridgebio.com
CUSIP:10806X102
CIK:0001743881
ISIN:US10806X1028
FIGI:BBG00P9KDZK6
LEI:54930028YG89VTY2J114

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:82.041.1%
MA10:82.620.4%
MA20:79.424.4%
MA50:72.1714.9%
MA100:71.6815.7%
MA200:70.5417.6%
STO9:51.77
STO14:33.07
RSI14:59.99
WPR14:-58.29
MTM14:5.18
ROC14:0.07 
ATR:3.75 
Week High:83.530.7%
Week Low:78.985.0%
Month High:93.4212.6%
Month Low:68.0317.6%
Year High:93.4212.6%
Year Low:42.0997.0%